secwatch.observer — SEC 8-K summary
======================================

Issuer:     BRISTOL MYERS SQUIBB CO (BMY)
CIK:        0000014272
Form:       8-K
Filed at:   2022-07-27T23:59:59+00:00
Accession:  0000014272-22-000164
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bristol-Myers Q2 revenue $11.9B (+2% YoY); Non-GAAP EPS $1.93 (+18%); GAAP EPS guidance adjusted
--------------------------------------------------------------------------------

- Q2 revenue $11.887B, up 2% (5% ex-FX); U.S. revenue +12% to $8.3B, international revenue -16% (-8% ex-FX).
- GAAP EPS $0.66 (up 40%); non-GAAP EPS $1.93 (up 18%); GAAP net earnings $1.4B vs $1.1B.
- In-line product revenue +11% YoY (Eliquis +16%, Opdivo +8%); Revlimid -22% on generic erosion.
- New product portfolio added $257M (Abecma, Opdualag, Reblozyl); Acquired IPRD charges $400M.
- 2022 GAAP EPS guidance adjusted; non-GAAP EPS guidance reaffirmed; dividend maintained at $0.54/share.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/14272/000001427222000164/0000014272-22-000164-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/14272/000001427222000164/bmy-20220727.htm
  HTML page:      https://secwatch.observer/filing/0000014272-22-000164

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer